Skip to content

Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population

Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04270201
Acronym
ALDH2020
Enrollment
300
Registered
2020-02-17
Start date
2022-01-02
Completion date
2023-12-01
Last updated
2021-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Squamous Cell Carcinoma (OSCC)

Keywords

Oral squamous cell carcinoma, ALDH1b1, ALDH2, polymorphism

Brief summary

A case-control study with oral squamous cell carcinoma (OSCC) patients from Instituto do Câncer do Estado de São Paulo (ICESP) and healthy volunteers. In this study, it will be collected saliva samples from both groups that will be submitted to sequencing analysis to evaluate the frequency of ALDH1b1 and ALDH2 polymorphisms in the Brazilian population. Also, correlate OSCC risk to alcohol consumption or smoke, by applied questionnaires.

Detailed description

According to the World Health Organization (WHO), in 2016 there were 3 million deaths worldwide from alcohol abuse. ALDH1b1 and ALDH2 proteins are involved in the alcohol metabolism promoting the conversion of acetaldehyde to acetate. The genes that encode these proteins have genetic variants, also called polymorphisms, that can promote changes in their functions such as the accumulation of acetaldehyde in the body, resulting in facial flushing, tachycardia and headache. Studies reported the correlation between alcohol consumption and/or smoking and these polymorphisms to a higher risk for head and neck cancer, including oral squamous cell carcinoma (OSCC). The aim of this study is to determine the frequency of the ALDH1b1 and ALDH2 polymorphisms in the Brazilian population, in addition to estimating the risk for OSCC among those with polymorphisms. For this, unstimulated saliva samples will be collected from OSCC patients and healthy volunteers. All study participants must complete two questionnaires on alcohol consumption, smoking and disease history. Saliva samples will be collected using the DNA/RNA Shield Saliva Collection Kit and stored at -20ºC. The DNA will be extracted, quantified by the Nanodrop equipment and amplified by the polymerase chain reaction (PCR), using specific primers for each of the genetic variants. The PCR product will be sent to the Sequencing Service of the Centro de Pesquisas sobre o Genoma Humano e Células-Tronco/IBUSP, where the Sanger sequencing technique will be performed and the results will be analyzed in the ICB-USP laboratory. For the group of patients, medical records will be monitored to correlate clinical data and genetic variants with overall survival. These data will allow the characterization of the genetic variants of ALDH1b1 and ALDH2 in the Brazilian population and support the development of future public policies to reduce the main risk factors for OSCC, especially among those with these genetic variants.

Interventions

OTHERSaliva collection

Saliva collection

Sponsors

Instituto de Ciências Biomédicas da Universidade de São Paulo
CollaboratorUNKNOWN
Instituto do Cancer do Estado de São Paulo
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* OSCC diagnostic for case group * Able to read and sign the consent form. * Able for saliva collection. * Able to understand the applied questionnaires.

Exclusion criteria

* Unable to read and sign the consent form. * Unable for saliva collection. * Unable to understand the applied questionnaires. * OSCC patient's companions for healthy volunteers.

Design outcomes

Primary

MeasureTime frameDescription
Frequency of ALDH1b1 and ALDH2 polymorphisms1 yearDetermine the frequency of ALDH1b1 and ALDH2 polymorphisms in OSCC patients and healthy volunteers.

Secondary

MeasureTime frameDescription
Survival5 yearsOverall survival (case group)

Countries

Brazil

Contacts

Primary ContactIsabela C de Souza
isabelasouza@usp.br+5511982496744

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026